Latest news with #ESTRO2025
Yahoo
05-05-2025
- Business
- Yahoo
Nanobiotix Announces Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer
Results demonstrated favorable safety, injection feasibility, and encouraging oncologic outcomes in patients (n=22) with locally advanced or borderline resectable pancreatic cancer Median Overall Survival of 23 months from date of diagnosis [95% CI; 17 months – not reached] Median Local Progression-Free Survival of 13.3 months from completion of radiation Notable findings observed in exploratory biomarker analyses include: An association between increased circulating tumor mutational burden (cTMB) and LPFS and OS CA19-9 normalization in 59% of patients in the study, and an association between CA19-9 normalization and OS First patient injected in a new cohort that adds standard-of-care concurrent chemotherapy (capecitabine or 5-FU) to radiotherapy-activated JNJ-1900 (NBTXR3) and recruitment is ongoing Investigators concluded that these results support further evaluation in a randomized study Data presented at the 2025 Annual Meeting of the European Society of Radiation Oncology PARIS and CAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ''Company''), a late-stage clinical biotechnology company pioneering nanotherapeutic approaches to improve treatment outcomes for patients with cancer, today announced the presentation of full results from the completed dose escalation and dose expansion phases of a Phase 1 study evaluating JNJ-1900 (NBTXR3) in patients with locally advanced or borderline resectable pancreatic cancer. The study, conducted by The University of Texas MD Anderson Cancer Center ('MD Anderson'), was presented by principal investigator Dr. Eugene Koay at the 2025 Annual Meeting of the European Society for Radiotherapy and Oncology (ESTRO 2025). Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, driven by aggressive tumor biology and limited responsiveness to standard therapies. For patients with locally advanced ('LAPC') or borderline resectable ('BRPC') disease, the current standard-of-care ('SOC')—induction chemotherapy followed by chemoradiation—rarely delivers curative outcomes, underscoring the need for novel treatment approaches. 'Patients with locally advanced or borderline resectable pancreatic cancer face a particularly urgent unmet need for therapeutic innovation that can provide a meaningful survival benefit with an acceptable safety profile,' said Eugene Koay, MD, PhD, Associate Professor of Radiation Oncology at MD Anderson. 'We are encouraged by the results from the completed cohorts and look forward to the continued evaluation of JNJ-1900 (NBTXR3) in combination with standard-of-care chemoradiation after induction chemotherapy.' PRESENTATION #E25-2265: NANORAY Pancreas: A Phase 1 Study of NBTXR3 (JNJ-1900) Activated by Radiotherapy for Locally Advanced or Borderline Resectable Pancreatic Cancer (LAPC or BRPC)Koay EJ, Liu S, Guerrero P, Stokes E, Katz MHG, Ikoma N, Snyder RA, Tzeng CD, Overman MJ, Pant S, Wolff RA, Javle M, Holliday EB, Ludmir EB, Das P, Noticewala S, Koong AC, Tamm EP, Bhutani M This MD Anderson-sponsored Phase 1 study evaluated the potential of radiotherapy('RT')-activated JNJ-1900 (NBTXR3) activated by radiation therapy (45 Gy in 15 fractions) to overcome inherent radioresistance in patients with LAPC or BRPC. The majority of patients in the study (20/22) were diagnosed with locally advanced, unresectable disease (LAPC). For clarity, patients with LAPC or BRPC are traditionally treated with induction chemotherapy followed by concurrent chemoradiation. The treatment regimen in the completed dose escalation and dose expansion parts of this Phase 1 study replaced concurrent chemoradiation with RT-activated JNJ-1900 (NBTXR3) after induction chemotherapy. Key Results: Favorable safety profile and injection feasibility were observed (n=22) Median overall survival ('mOS'): 23 months from diagnosis [95% CI; 17 months – not reached] For context, an MD Anderson historical review of 144 patients with LAPC treated at the same center showed a mOS of 19.2 months. Patients in the historical review received induction chemotherapy followed by RT with or without concurrent or maintenance chemotherapy (80% received RT with concurrent chemotherapy) Median local progression-free survival ('mLPFS'): 13.3 months from completion of radiation Two LAPC patients achieved R0 surgical resection Exploratory Biomarker Analyses: Of the 20 patients for whom circulating Tumor Mutational Burden (cTMB) data was available, a notable proportion (40%; 8/20) exhibited increased cTMB, and investigators observed an association between increased cTMB and improved LPFS and OS Normalization of CA19-9, a surrogate for overall survival benefit, was observed in 59% of patients (11/22) and was associated with longer survival in the study. For context, an MD Anderson historical review of 243 patients with LAPC treated at the same center showed normalization of CA19-9 in approximately 17% of patients treated with the standard of care who had elevated CA19-9 levels at diagnosis Based on the safety and preliminary efficacy findings, investigators concluded that further evaluation of JNJ-1900 (NBTXR3) is warranted in a randomized study. 'Our collaboration with MD Anderson has always been driven by a shared commitment to exploring bold new approaches for patients with high unmet need,' said Louis Kayitalire, MD, Chief Medical Officer at Nanobiotix. 'Given the extremely poor survival rates in LAPC and BRPC, the results from this Phase 1 study give us confidence in the potential of JNJ-1900 (NBTXR3) to serve as a meaningful addition to the treatment landscape. We are particularly excited about the potential to further enhance outcomes through combination of JNJ-1900 (NBTXR3) with SOC chemoradiation in the study's new active cohort, and we look forward to advancing this program in pancreatic cancer.' MD Anderson received FDA clearance to expand the study to include a new cohort that combines of JNJ-1900 (NBTXR3) with SOC concurrent chemoradiation after induction chemotherapy. The first patient in the new cohort has been injected, and recruitment is ongoing. Nanobiotix Conference Call Nanobiotix will host a conference call and webcast featuring Nanobiotix Chief Executive Officer and Chairman of the Executive Board, Laurent Levy, to discuss the data on Monday May 5th, 2025, at 8:00 AM EDT / 2:00 PM CEST. Details for the call are as follows: Webcast link: click here Audio-only dial-in link: click here Participants can use the audio-only link above to register and obtain dial-in instructions to listen to the presentation via phone and ask questions during the Q&A session, or participants can use the webcast link to register and listen and watch the slide presentation online; the replay version will be available under the same webcast link shortly after the presentation and will be archived on the Company's website at It is recommended to join 10 minutes prior to the event start. Participants are invited to email their questions in advance to investors@ About JNJ-1900 (NBTXR3) JNJ-1900 (NBTXR3) is a novel, potentially first-in-class oncology product composed of functionalized hafnium oxide nanoparticles that is administered via one-time intratumoral injection and activated by radiotherapy. Its proof-of-concept was achieved in soft tissue sarcomas through a successful randomized Phase 2/3 study in 2018. The product candidate's physical mechanism of action (MoA) is designed to induce significant tumor cell death in the injected tumor when activated by radiotherapy, subsequently triggering adaptive immune response and long-term anti-cancer memory. Given the physical MoA, Nanobiotix believes that JNJ-1900 (NBTXR3) could be scalable across any solid tumor that can be treated with radiotherapy and across any therapeutic combination, particularly immune checkpoint inhibitors. Radiotherapy-activated JNJ-1900 (NBTXR3) is being evaluated across multiple solid tumor indications as a single agent or combination therapy. The program is led by NANORAY-312—a global, randomized Phase 3 study in locally advanced head and neck squamous cell cancers. In February 2020, the United States Food and Drug Administration granted regulatory Fast Track designation for the investigation of JNJ-1900 (NBTXR3) activated by radiation therapy, with or without cetuximab, for the treatment of patients with locally advanced HNSCC who are not eligible for platinum-based chemotherapy—the same population being evaluated in the Phase 3 study. Given the Company's focus areas, and balanced against the scalable potential of NBTXR3, Nanobiotix has engaged in a collaboration strategy to expand development of the product candidate in parallel with its priority development pathways. Pursuant to this strategy, in 2019 Nanobiotix entered into a broad, comprehensive clinical research collaboration with The University of Texas MD Anderson Cancer Center to sponsor several Phase 1 and Phase 2 studies evaluating JNJ-1900 (NBTXR3) across tumor types and therapeutic combinations. In 2023, Nanobiotix announced a license agreement for the global co-development and commercialization of JNJ-1900 (NBTXR3) with Janssen Pharmaceutica NV, a Johnson & Johnson company. About NANOBIOTIX Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company's philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life. Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations. Nanobiotix is the owner of more than 25 umbrella patents associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system. For more information about Nanobiotix, visit us at or follow us on LinkedIn and Twitter Disclaimer This press release contains 'forward-looking' statements within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the use of proceed therefrom, and the period of time through which the Company's anticipates its financial resources will be adequate to support operations. Words such as 'expects', 'intends', 'can', 'could', 'may', 'might', 'plan', 'potential', 'should' and 'will' or the negative of these and similar expressions are intended to identify forward-looking statements. These forward-looking statements which are based on the Company' management's current expectations and assumptions and on information currently available to management. These forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those implied by the forward-looking statements, including risks related to Nanobiotix's business and financial performance, which include the risk that assumptions underlying the Company's cash runway projections are not realized. Further information on the risk factors that may affect company business and financial performance is included in Nanobiotix's Annual Report on Form 20-F filed with the SEC on April 02, 2025 under 'Item 3.D. Risk Factors', in Nanobiotix's 2024 universal registration document filed with the AMF on April 02, 2025,, and subsequent filings Nanobiotix makes with the SEC from time to time which are available on the SEC's website at The forward-looking statements included in this press release speak only as of the date of this press release, and except as required by law, Nanobiotix assumes no obligation to update these forward-looking statements publicly. Contacts Nanobiotix Communications DepartmentBrandon OwensVP, Communications+1 (617) 852-4835contact@ Investor Relations DepartmentRicky BhajunDirector, Investor Relations+33 (0) 79 97 29 99investors@ Media Relations France – HARDYCaroline Hardy+33 06 70 33 49 50carolinehardy@ Global – uncapped CommunicationsBecky Lauer +1 (646) 286-0057 nanobiotixteam@ Attachment 2025-05-05 -- NBTX -- Full Ph1 NBTXR3 Results in Pancreatic Cancer -- FINALSign in to access your portfolio
Telegraph
03-05-2025
- Health
- Telegraph
Two weeks of prostate cancer radiotherapy still saves lives, study finds
For many patients, radiotherapy is a standard treatment option that offers outcomes comparable to surgery, particularly for localised disease but schedules typically span several weeks, which can be burdensome for patients and put pressure on healthcare systems. For the new trial, 1,200 men with localised cancer were given either a short course of seven sessions over two and a half weeks, or a standard course of 39 sessions over eight weeks. Results showed that 72 per cent of men having the shorter treatment did not see their cancer return and did not need more treatment within the next 10 years, compared to 65 per cent of men in the standard group. Overall survival for the two-week group was 81 per cent compared with 79 per cent for traditional treatment. For both groups four per cent of men died from their cancer in the 10-year follow up. The shorter treatment group needed a total radiation of 42.7 gy (the unit for absorbed dose) compared to 72 gy for the eight-week group. Side effects were similar in both groups and were mostly mild to moderate. 'These findings confirm that the shorter course does not increase long-term side effects and provides equally durable cancer control', added Dr Camilla Thellenberg-Karlsson, of Umeå University. 'A major win' for patients The findings were welcomed by charities. Simon Grieveson, assistant director of research at Prostate Cancer UK, said: 'We welcome these results. It's fantastic news for men that this has shown the long-term benefits of a shorter course of radiotherapy, meaning that they could still receive the best possible treatment with fewer visits to the hospital. 'We've previously seen similar results from the UK-based PACE B trial, which has shown that using stereotactic ablative body radiotherapy – a form of radiotherapy which delivers high doses of radiation directly to tumours, reducing exposure to healthy tissue around the cancer – can cut down the number of treatment sessions to just five over a two-week period. 'These studies show us that shorter courses of radiotherapy can be just as effective for men compared to the more extensive radiotherapy regimes more commonly used.' The research was presented at ESTRO 2025, the annual congress of the European Society for Radiotherapy and Oncology. Prof Matthias Guckenberger, president of ESTRO, added: 'Shorter treatment schedules mean patients can return to their normal lives more quickly. 'Reducing treatment time to just two and a half week is a major win for both patients and health systems.'
Business Wire
30-04-2025
- Business
- Business Wire
Sun Nuclear Acquires Oncospace, AI-Focused Radiation Oncology Software Provider
MELBOURNE, Fla.--(BUSINESS WIRE)--Sun Nuclear, a Mirion Medical company, today announced the acquisition of Oncospace, a company providing cloud-based, AI-powered solutions for the radiation oncology community. This strategic move underscores the Sun Nuclear commitment to leverage cutting-edge technology to improve treatment outcomes on behalf of our customers. Oncospace's AI and machine-learning technologies are designed to develop data-driven, physician-centric solutions that optimize patient outcomes. Since its inception in 2018, Oncospace has launched two main offerings: Gateway: A Treatment Planning Conversion solution for Philips Pinnacle users, which converts patient archives to modern treatment planning solutions, such as Raysearch Raystation and Varian Medical Systems® Eclipse. While originally developed for prostate treatments, this solution has since expanded to head and neck radiotherapy, with future offerings planned. A Predictive Plan Quality and Feasibility solution, which leverages the AI approach of machine learning to analyze thousands of clinical treatment plans and derive achievable, best-practice dosimetry goals for plan optimization and evaluation. 'We are excited to welcome Oncospace into the Sun Nuclear family,' said Luis Rivera, Sun Nuclear president and Mirion Medical executive vice president. 'By incorporating the Oncospace solutions dependent on AI and machine-learning capabilities, Sun Nuclear is affirming our commitment to drive innovation in radiation therapy. We look forward to the positive impact this will have on our software roadmap.' By informing actions through harnessing vital information, the Oncospace offerings address the demands of radiation oncology professionals while improving the precision and efficiency of radiation therapy planning, thus enhancing the overall quality of care and outcomes. This acquisition aligns with the Sun Nuclear focus of enhancing the quality and accessibility of radiation therapy, ensuring that patients receive the best possible treatment. Oncospace software will be featured in Sun Nuclear's booth at ESTRO 2025, May 2-6, in Vienna, Austria. ESTRO is the annual congress for the European Society for Radiotherapy and Oncology and includes Europe's largest industry exhibition in radiation oncology. About Sun Nuclear Sun Nuclear is part of Mirion Medical, a group of healthcare-focused brands within Mirion , providing innovative solutions for Radiation Therapy and Diagnostic Imaging centers. More than 6,000 cancer centers worldwide rely on Sun Nuclear for independent, integrated Quality Management. With a focus on ongoing support, Sun Nuclear aims to ease technology adoption, enhance workflows and improve outcomes – so that healthcare providers can achieve real results for Patient Safety. Learn more:
Yahoo
30-04-2025
- Business
- Yahoo
Nanobiotix Announces Presentation of Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Followed by a Conference Call
Full results from the completed dose escalation part and dose expansion parts of a Phase 1 study evaluating JNJ-1900 (NBTXR3) after induction chemotherapy for patients with locally advanced or borderline resectable pancreatic cancer to be presented by Principal Investigator Eugene Koay, MD, at ESTRO 2025 on Sunday, May 4th at 11:00 AM EDT / 5:00 PM CEST Nanobiotix will host an event on Monday, May 5th at 8:00 AM EDT / 2:00 PM CEST to review the presented results PARIS and CAMBRIDGE, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ''Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced the presentation of full results from the completed dose escalation and dose expansion parts of a Phase 1 study evaluating JNJ-1900 (NBTXR3) in patients with locally advanced or borderline resectable pancreatic cancer. The study, conducted by The University of Texas MD Anderson Cancer Center, will be presented by principal investigator Dr. Eugene Koay on Sunday, May 4th at 11:00 AM EDT / 5:00 PM CEST during the 2025 Annual Meeting of the European Society for Radiotherapy and Oncology (ESTRO 2025). PRESENTATION #E25-2265: NANORAY Pancreas: A Phase 1 Study of NBTXR3 (JNJ-1900) Activated by Radiotherapy for Locally Advanced or Borderline Resectable Pancreatic Cancer (LAPC or BRPC)Koay EJ, Liu S, Guerrero P, Stokes E, Katz MHG, Ikoma N, Snyder RA, Tzeng CD, Overman MJ, Pant S, Wolff RA, Javle M, Holliday EB, Ludmir EB, Das P, Noticewala S, Koong AC, Tamm EP, Bhutani M Nanobiotix ConferenceCall Nanobiotix will host a conference call and webcast featuring Nanobiotix chief executive officer and chairman of the executive board, Laurent Levy, to discuss the data on Monday May 5th, 2025, at 8:00 AM EDT / 2:00 PM CEST. Details for the call are as follows: Webcast link: click here Audio-only dial-in link: click here Participants can use the audio-only link above to register and obtain dial-in instructions to listen to the presentation via phone and ask questions during the Q&A session, or participants can use the webcast link to register and listen and watch the slide presentation online; the replay version will be available under the same webcast link shortly after the presentation and will be archived on the Company's website at It is recommended to join 10 minutes prior to the event start. Participants are invited to email their questions in advance to investors@ About JNJ-1900 (NBTXR3) NBTXR3 is a novel, potentially first-in-class oncology product composed of functionalized hafnium oxide nanoparticles that is administered via one-time intratumoral injection and activated by radiotherapy. Its proof-of-concept was achieved in soft tissue sarcomas for which the product received a European CE mark in 2019. The product candidate's physical mechanism of action (MoA) is designed to induce significant tumor cell death in the injected tumor when activated by radiotherapy, subsequently triggering adaptive immune response and long-term anti-cancer memory. Given the physical MoA, Nanobiotix believes that NBTXR3 could be scalable across any solid tumor that can be treated with radiotherapy and across any therapeutic combination, particularly immune checkpoint inhibitors. Radiotherapy-activated NBTXR3 is being evaluated across multiple solid tumor indications as a single agent or in combination with anti-PD-1 immune checkpoint inhibitors, including in NANORAY-312—a global, randomized Phase 3 study in locally advanced head and neck squamous cell cancers. In February 2020, the United States Food and Drug Administration granted regulatory Fast Track designation for the investigation of NBTXR3 activated by radiation therapy, with or without cetuximab, for the treatment of patients with locally advanced HNSCC who are not eligible for platinum-based chemotherapy—the same population being evaluated in the Phase 3 study. Given the Company's focus areas, and balanced against the scalable potential of NBTXR3, Nanobiotix has engaged in a collaboration strategy to expand development of the product candidate in parallel with its priority development pathways. Pursuant to this strategy, in 2019 Nanobiotix entered into a broad, comprehensive clinical research collaboration with The University of Texas MD Anderson Cancer Center to sponsor several Phase 1 and Phase 2 studies evaluating NBTXR3 across tumor types and therapeutic combinations. In 2023, Nanobiotix announced a license agreement for the global co-development and commercialization of NBTXR3 with Janssen Pharmaceutica NV, a Johnson & Johnson company. About NANOBIOTIX Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company's philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life. Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations. Nanobiotix is the owner of more than 25 umbrella patents associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system. For more information about Nanobiotix, visit us at or follow us on LinkedIn and Twitter Disclaimer This press release contains 'forward-looking' statements within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the use of proceed therefrom, and the period of time through which the Company's anticipates its financial resources will be adequate to support operations. Words such as 'expects', 'intends', 'can', 'could', 'may', 'might', 'plan', 'potential', 'should' and 'will' or the negative of these and similar expressions are intended to identify forward-looking statements. These forward-looking statements which are based on the Company' management's current expectations and assumptions and on information currently available to management. These forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those implied by the forward-looking statements, including risks related to Nanobiotix's business and financial performance, which include the risk that assumptions underlying the Company's cash runway projections are not realized. Further information on the risk factors that may affect company business and financial performance is included in Nanobiotix's Annual Report on Form 20-F filed with the SEC on April 02, 2025 under 'Item 3.D. Risk Factors', in Nanobiotix's 2024 universal registration document filed with the AMF on April 02, 2025,, and subsequent filings Nanobiotix makes with the SEC from time to time which are available on the SEC's website at The forward-looking statements included in this press release speak only as of the date of this press release, and except as required by law, Nanobiotix assumes no obligation to update these forward-looking statements publicly. Contacts Nanobiotix Communications DepartmentBrandon OwensVP, Communications+1 (617) 852-4835contact@ Investor Relations DepartmentRicky BhajunDirector, Investor Relations+33 (0)6 42 05 34 15investors@ Media Relations France – HARDYCaroline Hardy+33 06 70 33 49 50carolinehardy@ Global – uncapped Communicationsnanobiotixteam@ Attachment 2025-04-30 -- NBTX -- Ph1 NBTXR3 Data Save-the-Date -- FINALSign in to access your portfolio
Business Wire
22-04-2025
- Business
- Business Wire
Sun Nuclear Announces Completion of Transition to CE Class IIb EU MDR Certification for Key Quality Management Solutions
MELBOURNE, Fla.--(BUSINESS WIRE)-- Sun Nuclear, a Mirion Medical company, announced today that its SunCHECK ® Quality Management software and key radiation therapy Quality Assurance (QA) devices have been awarded CE Class IIb certification under the European Medical Devices Regulation 2017/745 (EU MDR). The transition to EU MDR Class IIb recognizes the safety and performance of Sun Nuclear solutions and confirms compliance with stringent safety requirements. Sun Nuclear solutions awarded Class IIb certification include: The SunCHECK ® Platform, a comprehensive software application facilitating essential Patient and Machine QA workflows and centralized data management; Patient-specific QA solutions, including the ArcCHECK ®, ArcCHECK ® -MR, MapCHECK ® 3 and SRS MapCHECK ® devices, for measurement of radiation dose distributions against planned doses; Machine QA solutions, including the Daily QA™ 3, Daily QA™ 3-MR, IC PROFILER™, IC PROFILER™-MR devices, for routine QA of linear accelerators used in treatment delivery; and Beam Dosimetry, Scanning and Commissioning solutions, including: the 1D SCANNER™ and SunSCAN 3D™ water tanks; the PC Electrometer™ for absolute dose calibration and EDGE™ Detector for small-field beam modeling; and SNC125c™, SNC350p™ and SNC600c™ reference ion chambers. 'For 40 years, Sun Nuclear devices and software have helped radiation oncology and medical physics teams confidently adopt new technologies and techniques, enhance workflows, and improve patient care,' said Luis Rivera, president of Sun Nuclear and executive vice president of Mirion Medical. 'The transition to Class IIb EU MDR certification reinforces our commitment to safe, efficient, and effective cancer treatment globally, and further positions the company for ongoing success in Europe.' The Sun Nuclear portfolio will be featured in booth #280 at ESTRO 2025, May 2-6, in Vienna, Austria. ESTRO 2025 is the annual congress for the European Society for Radiotherapy and Oncology and includes Europe's largest industry exhibition in radiation oncology. About Sun Nuclear Sun Nuclear is part of Mirion Medical, a group of healthcare-focused brands within Mirion, providing innovative solutions for Radiation Therapy and Diagnostic Imaging. More than 6,000 cancer centers worldwide rely on us for independent, integrated Quality Management. With a focus on ongoing support, Sun Nuclear aims to ease technology adoption, enhance workflows and improve outcomes – so that healthcare providers can achieve real results for Patient Safety. Learn more:
